These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 10633549

  • 1. A pharmacokinetic modeling of inorganic arsenic: a short-term oral exposure model for humans.
    Yu D.
    Chemosphere; 1999 Dec; 39(15):2737-47. PubMed ID: 10633549
    [Abstract] [Full Text] [Related]

  • 2. A physiologically based pharmacokinetic model of inorganic arsenic.
    Yu D.
    Regul Toxicol Pharmacol; 1999 Apr; 29(2 Pt 1):128-41. PubMed ID: 10341143
    [Abstract] [Full Text] [Related]

  • 3. Development of a human physiologically based pharmacokinetic (PBPK) model for inorganic arsenic and its mono- and di-methylated metabolites.
    El-Masri HA, Kenyon EM.
    J Pharmacokinet Pharmacodyn; 2008 Feb; 35(1):31-68. PubMed ID: 17943421
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of a Physiologically Based Pharmacokinetic (PBPK) Model for Inorganic Arsenic Exposure Using Data from Two Diverse Human Populations.
    El-Masri HA, Hong T, Henning C, Mendez W, Hudgens EE, Thomas DJ, Lee JS.
    Environ Health Perspect; 2018 Jul; 126(7):077004. PubMed ID: 30024383
    [Abstract] [Full Text] [Related]

  • 5. A physiologically based pharmacokinetic model for arsenic exposure. I. Development in hamsters and rabbits.
    Mann S, Droz PO, Vahter M.
    Toxicol Appl Pharmacol; 1996 Mar; 137(1):8-22. PubMed ID: 8607145
    [Abstract] [Full Text] [Related]

  • 6. Tissue distribution and urinary excretion of inorganic arsenic and its methylated metabolites in C57BL6 mice following subchronic exposure to arsenate in drinking water.
    Kenyon EM, Hughes MF, Adair BM, Highfill JH, Crecelius EA, Clewell HJ, Yager JW.
    Toxicol Appl Pharmacol; 2008 Nov 01; 232(3):448-55. PubMed ID: 18706920
    [Abstract] [Full Text] [Related]

  • 7. Physiologically based pharmacokinetic modeling of arsenic in the mouse.
    Gentry PR, Covington TR, Mann S, Shipp AM, Yager JW, Clewell HJ.
    J Toxicol Environ Health A; 2004 Jan 09; 67(1):43-71. PubMed ID: 14668111
    [Abstract] [Full Text] [Related]

  • 8. [Effect of glutathione and methionine on the distribution and methylic metabolism of arsenic speciation in mice exposed to arsenic through drinking water].
    Zhong Y, Yu X, Qu C, Niu Y.
    Wei Sheng Yan Jiu; 2008 Jul 09; 37(4):390-2, 396. PubMed ID: 18839517
    [Abstract] [Full Text] [Related]

  • 9. A physiologically based pharmacokinetic model for arsenic exposure. II. Validation and application in humans.
    Mann S, Droz PO, Vahter M.
    Toxicol Appl Pharmacol; 1996 Oct 09; 140(2):471-86. PubMed ID: 8887465
    [Abstract] [Full Text] [Related]

  • 10. Assessment of exposure to inorganic arsenic by determining the arsenic species excreted in urine.
    Hakala E, Pyy L.
    Toxicol Lett; 1995 May 09; 77(1-3):249-58. PubMed ID: 7618147
    [Abstract] [Full Text] [Related]

  • 11. Inorganic arsenic methylation by rat tissue slices.
    Georis B, Cardenas A, Buchet JP, Lauwerys R.
    Toxicology; 1990 Jul 09; 63(1):73-84. PubMed ID: 2382271
    [Abstract] [Full Text] [Related]

  • 12. Tissue dosimetry, metabolism and excretion of pentavalent and trivalent monomethylated arsenic in mice after oral administration.
    Hughes MF, Devesa V, Adair BM, Styblo M, Kenyon EM, Thomas DJ.
    Toxicol Appl Pharmacol; 2005 Oct 15; 208(2):186-97. PubMed ID: 16183392
    [Abstract] [Full Text] [Related]

  • 13. Kinetics of arsenic methylation by freshly isolated B6C3F1 mouse hepatocytes.
    Kedderis GL, Elmore AR, Crecelius EA, Yager JW, Goldsworthy TL.
    Chem Biol Interact; 2006 Jun 10; 161(2):139-45. PubMed ID: 16725132
    [Abstract] [Full Text] [Related]

  • 14. Systemic uptake of inhaled arsenic in rabbits.
    Beck BD, Slayton TM, Farr CH, Sved DW, Crecelius EA, Holson JF.
    Hum Exp Toxicol; 2002 Apr 10; 21(4):205-15. PubMed ID: 12099622
    [Abstract] [Full Text] [Related]

  • 15. Biliary and urinary excretion of inorganic arsenic: monomethylarsonous acid as a major biliary metabolite in rats.
    Gregus Z, Gyurasics A, Csanaky I.
    Toxicol Sci; 2000 Jul 10; 56(1):18-25. PubMed ID: 10869450
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics, metabolism, and carcinogenicity of arsenic.
    Pott WA, Benjamin SA, Yang RS.
    Rev Environ Contam Toxicol; 2001 Jul 10; 169():165-214. PubMed ID: 11330077
    [Abstract] [Full Text] [Related]

  • 17. Tissue distribution and urinary excretion of inorganic arsenic and its methylated metabolites in mice following acute oral administration of arsenate.
    Kenyon EM, Del Razo LM, Hughes MF.
    Toxicol Sci; 2005 May 10; 85(1):468-75. PubMed ID: 15703264
    [Abstract] [Full Text] [Related]

  • 18. Research toward the development of a biologically based dose response assessment for inorganic arsenic carcinogenicity: a progress report.
    Clewell HJ, Thomas RS, Gentry PR, Crump KS, Kenyon EM, El-Masri HA, Yager JW.
    Toxicol Appl Pharmacol; 2007 Aug 01; 222(3):388-98. PubMed ID: 17499324
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide.
    Fujisawa S, Ohno R, Shigeno K, Sahara N, Nakamura S, Naito K, Kobayashi M, Shinjo K, Takeshita A, Suzuki Y, Hashimoto H, Kinoshita K, Shimoya M, Kaise T, Ohnishi K.
    Cancer Chemother Pharmacol; 2007 Mar 01; 59(4):485-93. PubMed ID: 16937107
    [Abstract] [Full Text] [Related]

  • 20. Genetic polymorphism in the biotransformation of inorganic arsenic and its role in toxicity.
    Vahter M.
    Toxicol Lett; 2000 Mar 15; 112-113():209-17. PubMed ID: 10720733
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.